Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
about
The molecular rationale of Src inhibition in colorectal carcinomasTargeting Src family kinases in anti-cancer therapies: turning promise into triumphIn silico investigation of potential SRC kinase ligands from traditional Chinese medicineSLAP displays tumour suppressor functions in colorectal cancer via destabilization of the SRC substrate EPHA2.Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancerSrc activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Dasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Proteolysis of EphA2 Converts It from a Tumor Suppressor to an OncoproteinDasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.Targeting metastasis.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cellsEvaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.c-Src activity is differentially required by cancer cell motility modes.Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation.
P2860
Q26853018-5BE49B00-A58D-4544-BF9B-5A4964A644CCQ27025646-4894A9F0-8D94-4814-A1A6-E160176F8C8EQ28481644-619D115B-03FE-41A4-A645-EA549ECFE79DQ30009494-FB3B17E2-AF78-4B84-A0BC-E1D3565DD576Q33940893-5EB3AECA-337E-4EDE-9EEF-EC597649C9D5Q34203648-C42CAE6A-C720-4D73-8728-02F302B9FEABQ34480200-94295D53-D114-4B6D-B96F-69B9C916201BQ36014173-ECE9B2AB-8E01-4614-8E57-05F7576329B5Q36140620-BF2A3E1C-A506-4E49-814D-0C3D6B229191Q36380708-7306C751-14C1-484D-B4C8-CCCA8C920EC1Q37362851-EE1B1670-8064-41E4-BD54-6894D05439FBQ38554714-6FB9C25B-D0B5-47BB-900E-100CD404B9F3Q38768576-15D0E3D1-8EDC-4C87-9FA9-51A58AE3419FQ38786658-3224C2D4-8082-424C-9788-D390D2B42204Q38815335-E2C5D41C-B643-443C-B2D5-ED93740224CBQ42676688-E42B42CA-5F1B-415E-8FDD-72E8F8A0582AQ47094824-8DDFFA31-BB32-4397-A5A6-8EFCDD344804Q49595076-5FE9EF7E-D0DE-4F28-9840-5666621E6128Q54977781-36CA9BA9-A2E6-47A6-B16B-9263948E2E9C
P2860
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@ast
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@en
type
label
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@ast
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@en
prefLabel
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@ast
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@en
P2093
P2860
P1476
Dasatinib in previously treate ...... f Chicago Phase II Consortium.
@en
P2093
Bethany G Sleckman
Blase N Polite
David Taber
Hedy L Kindler
James A Knost
James A Wallace
Kristen Wroblewski
Manish R Sharma
Sanjiv Modi
Walter M Stadler
P2860
P2888
P304
P356
10.1007/S10637-011-9681-X
P577
2011-05-07T00:00:00Z